CEBPE Antibody

What is CEBPE and what cellular functions does it regulate?

CEBPE (CCAAT/enhancer-binding protein epsilon) is a transcription factor that binds to specific DNA sequences, influencing gene transcription involved in immune response and cellular differentiation. It plays a crucial role in the terminal differentiation of neutrophils and eosinophils . CEBPE functions primarily in the nucleus where it can form heterodimers with other C/EBP family members, such as C/EBP α and C/EBP β, enhancing its regulatory capacity and allowing coordinated response to various physiological stimuli .

Research has demonstrated that CEBPE is required for the promyelocyte-myelocyte transition in myeloid differentiation . Unlike some other C/EBP family members that have broader tissue expression patterns, CEBPE shows more restricted expression, primarily in myeloid lineage cells, making it an important factor in understanding immune system development.

What are the different isoforms of CEBPE and how do they affect antibody selection?

Human C/EBP-ε is expressed as four distinct isoforms (32, 30, 27, and 14 kDa) through differential RNA splicing, alternative promoters, and translational start sites . These isoforms have different functional properties:

• The 32/30 kDa isoforms typically function as transcriptional activators

• The 27 kDa isoform has been identified as a repressor that can specifically antagonize GATA-1 transactivation

• The 14 kDa isoform has unique regulatory properties

When selecting an antibody, researchers must consider which isoform(s) they wish to detect. Some antibodies, like the C/EBP ε Antibody (C-10) from Santa Cruz Biotechnology, detect all isoforms, while others might recognize specific isoforms . For instance, research by Liu et al. showed that the C/EBP-ε 27 isoform specifically interacts with GATA-1 and inhibits major basic protein-1 (MBP1) gene expression in eosinophil development . If studying isoform-specific functions, researchers must verify which isoforms their antibody recognizes.

What are the validated applications for CEBPE antibodies, and what sample types are appropriate?

Based on the information provided in the search results, CEBPE antibodies have been validated for multiple applications:

Appropriate sample types include:

• Human, mouse, and rat cell lines (e.g., Jurkat, HeLa, U937)

• Primary cells (especially myeloid lineage cells)

• Tissue sections (bone marrow, cerebral cortex)

• Undiluted body fluids and tissue homogenates for ELISA applications

When selecting samples, researchers should consider that CEBPE expression is highest in tissues and cells of myeloid origin, particularly in granulocytes at various stages of differentiation .

How should I optimize CEBPE antibody dilutions for specific applications?

Optimal dilution of CEBPE antibodies varies by application, antibody source, and target sample. Based on the search results, here are recommended starting dilution ranges:

• Western Blot: 1:500-1:2000 (Boster Bio antibody A03884-1) , 0.5-1.0 μg/ml (BioLegend) , 0.4-1.0 μg/ml (Abcam ab246861)

• Immunohistochemistry: 1:50 dilution (Abcam ab246861 for paraffin-embedded tissues)

• Immunofluorescence: 4-10 μg/ml (Abcam ab246861, R&D Systems)

• ChIP assay: 5 μg of antibody per experiment (GeneTex antibodies)

For optimization:

• Begin with the manufacturer's recommended dilution

• Perform a dilution series (typically 2-fold dilutions)

• Include appropriate positive and negative controls

• For Western blots, evaluate both signal intensity and background

• For IHC/IF, assess specific nuclear staining versus background and non-specific binding

As noted in the LI-COR protocol, "The recommendations provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user." Optimization is particularly important when working with different sample types or when transitioning between applications.

How can CEBPE antibodies be used to study interactions with other transcription factors?

CEBPE forms complexes with various transcription factors, including other C/EBP family members and non-C/EBP proteins like GATA-1. To study these interactions:

• Co-immunoprecipitation (Co-IP): Use anti-CEBPE antibodies to pull down protein complexes, then probe for interacting partners. For example, researchers demonstrated that "C/EBP-ε 27 physically interacts with GATA-1" using co-immunoprecipitations with antibodies to GATA-1 or C/EBP-ε .

• Proximity-dependent biotin identification coupled to mass spectrometry: This technique was used to investigate protein-protein interactions of mutant vs. wild-type C/EBPε as described by Liu et al. . The method involves:

  • Generating stable cell lines expressing tagged CEBPE

  • Using proximity labeling to identify proteins in close physical association

  • Mass spectrometry identification of interaction partners

• ChIP-sequencing: ChIP-seq can identify genomic regions where CEBPE and other transcription factors co-bind. The search results describe using ChIP-seq "to assess C/EBPε binding to chromatin in freshly isolated and LPS-stimulated cells."

• Sequential ChIP (Re-ChIP): To determine if CEBPE and another factor simultaneously occupy the same DNA regions, sequential immunoprecipitation can be performed with antibodies against both factors.

These approaches have revealed important functional relationships, such as the antagonistic relationship between C/EBP-ε 27 and GATA-1 in eosinophil-specific gene regulation .

What experimental approaches can be used to study the role of CEBPE mutations in immune disorders?

Several experimental approaches have been employed to study CEBPE mutations and their relationship to immune disorders:

• Whole-exome sequencing: Used to identify CEBPE mutations in affected individuals, as demonstrated in a Finnish family study where the Arg219His mutation was discovered .

• Functional validation using cell lines:

  • Generate stable cell lines expressing wild-type or mutant CEBPE variants

  • Compare protein-protein interactions, DNA binding, and transcriptional activity

  • Example: "Flp-In T-REx 293 cell lines stably expressing mutant or wild-type (WT) C/EBPε were generated and used to investigate PPIs"

• Primary cell studies from mutation carriers:

  • Extract granulocytes from patients and controls

  • Perform ChIP-seq to assess DNA binding patterns

  • Use RNA-seq for genome-wide transcriptional profiling

  • Analyze responses to stimulants such as bacterial DNA, LPS, and interferons

• Specific functional assays:

  • Assess caspase activity using flow cytometry

  • Measure cytokine secretion (IL-1β/IL-18) using ELISA

  • Examine granule exocytosis and NF-κB phosphorylation

  • Evaluate subcellular morphology using electron microscopy

These approaches have revealed that CEBPE mutations can lead to noncanonical autoinflammatory disorders by affecting multiple cellular processes, including inflammasome activation and nuclear factor κB signaling.

What are the most effective validation strategies for ensuring CEBPE antibody specificity?

Thorough antibody validation is essential for ensuring experimental reproducibility and reliable results. Based on the search results, particularly from the nuclear receptor antibody validation study , effective strategies include:

• Multiple technique validation:

  • Western blotting with positive and negative controls

  • Immunohistochemistry on validation tissue microarrays (TMAs)

  • Correlation of IHC staining with mRNA expression data

  • Mass spectrometry verification of immunoprecipitated proteins

• Knockout/knockdown controls:

  • CEBPE knockout cells or tissues as negative controls

  • siRNA/shRNA knockdown samples to demonstrate antibody specificity

  • Overexpression systems as positive controls

• Peptide competition assays:

  • Pre-incubation of antibody with immunizing peptide should eliminate specific signal

  • "This protein band can be blocked by the synthesized immunogen peptide"

• Cross-reactivity assessment:

  • Testing against related C/EBP family members (C/EBPα, β, δ, γ)

  • Using cells with known expression patterns of different C/EBP proteins

• Isoform verification:

  • Using recombinant proteins of different isoforms

  • Comparing antibody reactivity against all known CEBPE isoforms (32, 30, 27, and 14 kDa)

The LI-COR protocol emphasizes recording validation experiments systematically: "The Review and report page allows you to export a PDF file containing the data and image from the validation or export the image and data table individually."

How can researchers address potential cross-reactivity issues with other C/EBP family members?

C/EBP family members share significant sequence homology, particularly in their DNA-binding and leucine zipper domains, making cross-reactivity a significant concern. Strategies to address this include:

• Epitope selection during antibody development:

  • Target unique regions of CEBPE that differ from other C/EBP proteins

  • The Boster Bio antibody (A03884-1) was produced against a synthesized peptide derived from human C/EBP-epsilon (AA range: 40-89), a region chosen for specificity

• Comprehensive testing against related proteins:

  • Test antibodies against recombinant C/EBPα, β, δ, and γ proteins

  • Include positive control lysates expressing each C/EBP family member

• Correlation with gene expression data:

  • Compare antibody reactivity with known mRNA expression patterns

  • "Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program"

• Molecular weight discrimination:

  • C/EBP family members have different molecular weights and isoform patterns

  • CEBPE is observed at approximately 39 kDa, while C/EBPα is detected at 42 kDa

  • C/EBPβ presents as multiple isoforms (31kD, 29kD and 16kD)

• Cell-type specificity checks:

  • Test in cells with differential expression of C/EBP family members

  • Utilize cells known to express high levels of CEBPE but low levels of other C/EBPs

When troubleshooting potential cross-reactivity, researchers should systematically eliminate each C/EBP family member using the above approaches and consider consulting the antibody manufacturer for specific information about epitope regions and cross-reactivity testing performed during antibody development.

What are common pitfalls in interpreting CEBPE protein expression data, and how can they be avoided?

Several common pitfalls can affect the interpretation of CEBPE protein expression data:

How do gain-of-function versus loss-of-function CEBPE mutations differentially affect immune function?

Research has identified both gain-of-function and loss-of-function mutations in CEBPE with distinct effects on immune function:

Gain-of-function mutations:

• The Arg219His mutation identified in a Finnish family causes a noncanonical autoinflammatory disorder

• This mutation results in enhanced binding to certain genomic regions and altered transcriptional regulation

• Functional studies showed that cells with this mutation exhibit:

  • Altered cytokine responses, particularly to bacterial stimuli

  • Changes in inflammasome activation and IL-1β/IL-18 secretion

  • Modified neutrophil granule formation and function

  • Increased susceptibility to certain infections despite heightened inflammatory responses

Loss-of-function mutations:

• Complete loss of CEBPE function leads to neutrophil-specific granule deficiency

• Knockout studies in mice have shown:

  • Reduced clearance of high-titer E. coli infections

  • Impaired macrophage infiltration and clearance of Klebsiella infection

  • Relative resistance to pneumococcal pneumonia due to reduced Pafr expression

  • Partial protection from LPS-induced sepsis and reduced inflammatory injury

The differential effects highlight the complex role of CEBPE in balancing immune activation and regulation. While loss-of-function mutations primarily affect neutrophil development and function, gain-of-function mutations can lead to dysregulated inflammation and immune responses to specific pathogens.

What methodological advances have improved the detection and characterization of CEBPE in complex biological samples?

Recent methodological advances have significantly improved CEBPE detection and characterization:

• Enhanced antibody validation protocols:

  • More rigorous validation using multiple techniques (WB, IHC, IF, ChIP)

  • Correlation with genomic and transcriptomic data for confirmation

  • Use of knockout controls and competition assays

  • As described in the nuclear receptor validation protocol: "Through correlation of immunohistochemical staining (IHC) and mRNA levels over multiple tissues, use of current public databases, and assessment of binding to intended and nonintended targets"

• Advanced ChIP-seq methodologies:

  • Improved protocols for transcription factor ChIP-seq with low cell numbers

  • Integration with other genomic datasets for comprehensive binding site analysis

  • Used effectively to study C/EBPε binding to chromatin in patient-derived cells

• Single-cell analysis techniques:

  • Single-cell RNA-seq to correlate CEBPE expression with cell states

  • Mass cytometry (CyTOF) for simultaneous detection of CEBPE with other markers

  • These approaches allow for characterization of CEBPE in heterogeneous samples like bone marrow

• Proximity labeling methods:

  • Proximity-dependent biotin identification coupled to mass spectrometry for protein-protein interaction studies

  • Enables detection of transient or weak interactions in living cells

• Digital detection methods:

  • Nanostring analysis for direct digital detection of mRNA levels of selected genes

  • Provides higher sensitivity and specificity compared to traditional methods

These methodological improvements have enabled researchers to better understand CEBPE's role in normal physiology and disease states, particularly in immune cell development and function.

How does CEBPE expression and function differ in various inflammatory and hematological disorders?

CEBPE shows distinct expression and functional patterns across inflammatory and hematological disorders:

Neutrophil-specific granule deficiency (SGD):

• Caused by loss-of-function mutations in CEBPE

• Characterized by abnormal neutrophil morphology and impaired function

• Neutrophils lack specific granule proteins and have bilobed nuclei

• Patients suffer from recurrent bacterial infections

Autoinflammatory disorders:

• Gain-of-function CEBPE mutations (e.g., Arg219His) cause noncanonical autoinflammatory conditions

• Features include:

  • Chronic neutrophilia

  • Recurrent fever episodes

  • Skin and joint manifestations

  • Abnormal response to bacterial stimuli

Acute myeloid leukemia (AML):

• CEBPE expression is often dysregulated in AML

• Decreased expression correlates with poor differentiation

• Restoration of CEBPE expression can induce differentiation of leukemic cells

• Functions downstream of CEBPA, which is frequently mutated in AML

Rheumatoid arthritis:

• C/EBPδ null mutation (a related family member) decreases collagen-induced arthritis

• Affected genes include Ccl20, Cxcl1, Il23a, and Tnfaip6

• Suggests potential involvement of CEBPE in inflammatory joint disease

The differential expression and function of CEBPE across these disorders highlight its importance in immune homeostasis and potential as a therapeutic target or biomarker.

What are the current approaches for using CEBPE antibodies in translational research applications?

CEBPE antibodies are being utilized in several translational research applications:

• Diagnostic marker development:

  • CEBPE expression patterns in bone marrow samples can help classify certain myeloid disorders

  • Immunohistochemical staining with anti-CEBPE antibodies provides cellular and subcellular localization information in patient samples

  • "Paraffin-embedded human bone marrow tissue stained for CEBPE using ab246861 at 1/50 dilution in immunohistochemical analysis"

• Drug response prediction:

  • CEBPE expression levels may predict response to differentiating agents in AML

  • Antibody-based detection of CEBPE in patient samples before and after treatment can guide therapy decisions

• Mechanistic studies of disease pathogenesis:

  • ChIP-seq with CEBPE antibodies helps identify dysregulated gene networks in disease

  • As demonstrated in the study of the Arg219His mutation: "ChIP-seq was used to assess C/EBPε binding to chromatin in freshly isolated and LPS-stimulated cells"

• Therapeutic target validation:

  • Assessing CEBPE levels and activity after experimental treatments

  • Using phospho-specific antibodies to evaluate activation state in response to pathway modulators

  • The antibodies-online.com kit specifically detects phosphorylated C/EBP-alpha (pSer21)

• Biomarker development for personalized medicine:

  • Correlation of CEBPE expression or localization with clinical outcomes

  • Development of standardized immunoassays for patient stratification

  • Integration with other molecular markers for comprehensive profiling

These translational applications bridge basic research findings on CEBPE to clinical applications, potentially improving diagnosis, prognostication, and treatment selection for patients with inflammatory and hematological disorders.